HVEM Proteins, Antibodies, cDNA Clones Research Reagents

TNFRSF14 (TNF Receptor Superfamily Member 14) is a protein coding gene located on human chromosome 1p36.32. TNFRSF14 is also known as TR2, ATAR, HVEA, HVEM, CD270 and LIGHTR. The human TNFRSF14 gene encodes a 30392 Da protein containing 283 amino acids. The TNFRSF14 protein is ubiquitously expressed in spleen, duodenum and other tissues. Among its related pathways are TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions and Akt Signaling. TNFRSF14 is related to ubiquitin protein ligase binding and tumor necrosis factor-activated receptor activity. TNFRSF1B is an important paralog of TNFRSF14 gene. TNFRSF14 is associated with some diseases, including Herpes Simplex and Nodal Marginal Zone Lymphoma.

HVEM Protein (11)

    HVEM Antibody (10)

      HVEM cDNA Clone (49)


      HVEM Lysate (8)

        More Product Popular With Customers

        HVEM Background

        Herpesvirus entry mediator (HVEM), also referred to as TNFRSF14, TR2 (TNF receptor-like molecule) and ATAR (another TRAF-associated receptor), is a member of type I transmembrane protein belonging to the TNF-receptor superfamily. It is expressed on many immune cells, including T and B cells, NK cells, monocytes, and neutrophils. Two TNF superfamily ligands lymphotoxin α (TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM and initiate the positive signaling. However, recent studies have revealed that HVEM is also involved in the unique inhibitory signaling pathway for T cells through activating tyrosine phosphorylation of the immunoreceptor tyrosine-based inhibitory motif (ITIM) in B and T lymphocyte attenuator (BTLA). HVEM provides a stimulatory signal following engagement with LIGHT (TNFSF14) on T cells. In contrast, it can also provide an inhibitory signal to T cells when it binds the B and T lymphocyte attenuator (BTLA), a ligand member of the Immunoglobulin (Ig) superfamily. Thus, HVEM may be viewed as a molecular switch, capable of facilitating both stimulatory and inhibitory cosignaling in T cells. Substantial evidence from both human disease and from experimental mouse models has indicated that dysregulation of the LIGHT-HVEM-BTLA cosignaling pathway can cause inflammation in the lung and in mucosal tissues.

        HVEM References

        • Murphy KM, et al. (2006) Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol. 6(9): 671-81.
        • Heo SK, et al. (2007) HVEM signaling in monocytes is mediated by intracellular calcium mobilization. J Immunol. 179(9): 6305-10.
        • Steinberg MW, et al. (2008) A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med. 205(6): 1463-76.
        • Pasero C, et al. (2009) A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production. Eur J Immunol. 39(9): 2502-14.
        • Cheung TC. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway. Recent Pat DNA Gene Seq. 3(3): 177-82.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.